FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 The Copaxone News Channel
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week
March 2005   
June 2005   
July 2005   
August 2005   
October 2005   
November 2005   
December 2005   
January 2006   
February 2006   
May 2006   
June 2006   
August 2006   
October 2006   
November 2006   
December 2008   
January 2013   
May 2013   
June 2013   
July 2013   
September 2013   
October 2013   
November 2013   
November 2014   
December 2014   
January 2015   
March 2015   
April 2015   
May 2015   
July 2015   
February 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Press Release: Surveyed U.S. Neurologists Would be Willing to Accept a Novel Primary-Progressive Multiple Sclerosis Therapy with Safety Risk if Proven Effective on Disability Progression

BURLINGTON, Mass.April 8, 2014 /PRNewswire/ -- Decision Resources Group (DRG) finds that, for the treatment of primary-progressive multiple sclerosis (PP-MS), surveyed U.S. neurologists would be willing to accept a certain level of risk for a therapy with proven efficacy on disability progression, likely owing to the absence of approved therapies for this indication.

This finding is reflected by the fact that among hypothetical therapies assessed in DRG's conjoint analysis tool, neurologists were most receptive to an agent with the greatest efficacy improvement over the market's sales leading therapy, Teva's Copaxone, but which was also associated with the greatest risk of serious or life threatening side effects.
Other key findings from the DecisionBase report entitled Chronic-Progressive Multiple Sclerosis: Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis?:
  • Unmet need: A therapy's effect on disability progression is weighted by surveyed U.S. and European neurologists as the most important efficacy attribute driving prescribing decisions for the treatment of PP-MS. However, according to available clinical data and interviewed experts' opinions, none of the profiled current or emerging therapies are differentiated from Copaxone on this attribute rendering it an area of high unmet need.
  • Nerventra: Nearly all surveyed U.S. neurologists would prescribe Teva's emerging product Nerventra, with it capturing 24 percent of currently treated PP-MS patient share. Although not yet studied in PP-MS, interest in Nerventra stems from the product's putative neuroprotective effect, benign safety profile to date and once-daily oral administration.  
Comments from Decision Resources Group Analyst Emma McFadden, Ph.D.:
  • "Data suggest that surveyed U.S. managed care organization pharmacy directors are highly receptive to novel PP-MS therapies offering even modest improvements over Copaxone on disability progression. However, they are sensitive to the risk profile of such agents when making formulary decisions, with few willing to reimburse a therapy with greater than one percent risk of serious adverse events. This reluctance is likely owing to the high costs which can be incurred by riskier therapies, such as by the need for patient monitoring and potential hospitalization."
  • "If proven effective in their respective ongoing PP-MS clinical trials, Novartis's Gilenya and Roche/Genentech's ocrelizumab both have considerable market potential. Even prior to the availability of PP-MS clinical data, surveyed U.S. neurologists indicate that they would prescribe these therapies to 20 percent of their currently treated PP-MS patients."
About Decision Resources Group Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more atwww.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Story Source: The above story is based on materials provided by PRNEWSWIRE
Note: Materials may be edited for content and length

Labels: ,